Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors
暂无分享,去创建一个
E. D. de Vries | J. Gietema | W. T. van der Graaf | D. V. van Veldhuisen | F. Boomsma | D. Sleijfer | P. Perik | J. Messerschmidt | W. V. D. van der Graaf
[1] Jing Ma,et al. Inflammatory markers and the risk of coronary heart disease in men and women. , 2004, The New England journal of medicine.
[2] W. Yin,et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. , 2004, American heart journal.
[3] A. V. van Roon,et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. , 2004, European journal of cancer.
[4] E. D. de Vries,et al. Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage. , 2004, European journal of cancer.
[5] S. Rodenhuis,et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. , 2003, The New England journal of medicine.
[6] B. A. Davis,et al. Tamoxifen induces apoptosis in Fas+ tumor cells by upregulating the expression of Fas ligand , 2003, Cancer Chemotherapy and Pharmacology.
[7] Patricia A. Ganz,et al. Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors , 2002, Psychosomatic medicine.
[8] Carmen Birchmeier,et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[9] S. Frøland,et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. , 2002, Cardiovascular research.
[10] M. P. van den Berg,et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Lip,et al. Abnormalities of Hemorheological, Endothelial, and Platelet Function in Patients With Chronic Heart Failure in Sinus Rhythm: Effects of Angiotensin-Converting Enzyme Inhibitor and &bgr;-Blocker Therapy , 2001, Circulation.
[12] D. Sleijfer,et al. Adsorptive Voltametry to Determine Platinum Levels in Plasma From Testicular Cancer Patients Treated With Cisplatin , 2001, Therapeutic drug monitoring.
[13] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[14] E. D. de Vries,et al. Long-term chemotherapy-related cardiovascular morbidity. , 2000, Cancer treatment reviews.
[15] B. Lloveras,et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] D. Sleijfer,et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer , 2000, The Lancet.
[17] G. Lip,et al. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. , 1999, Journal of the American College of Cardiology.
[18] J. Robertson,et al. C-erbB-2 in Serum of Patients with Breast Cancer , 1999, The International journal of biological markers.
[19] R. Nagai,et al. Elevated B-type natriuretic peptide levels after anthracycline administration. , 1998, American heart journal.
[20] H. Tunstall-Pedoe,et al. Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.
[21] M. Takemura,et al. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. , 1997, Journal of the American College of Cardiology.
[22] C A Beltrami,et al. Apoptosis in the failing human heart. , 1997, The New England journal of medicine.
[23] N. Kennedy,et al. Comparison of atrial natriuretic peptide B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. , 1996, The American journal of cardiology.
[24] H. Oral,et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.
[25] M. Pallardy,et al. Peripheral blood corticotropin-releasing factor, adrenocorticotropic hormone and cytokine (interleukin beta, interleukin 6, tumor necrosis factor alpha) levels after high- and low-dose total-body irradiation in humans. , 1994, Radiation research.
[26] A. Rosowsky,et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Berek,et al. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. , 1990, Cancer research.
[28] M. J. van de Vijver,et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.
[29] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.